Vaccine prospects for amebiasis

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 657-668

  Chaudhry, Omer A ^a   Petri Jr , William A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Acquired immunity; Amebiasis; Entamoeba histolytica; Gal GalNac lectin; Innate immunity; Vaccine

Indexed keywords

ANTIAMEBIC AGENT; CYSTEINE; CYSTEINE PROTEINASE; GALACTOSE; LECTIN; LIPOPHOSPHOGLYCAN; N ACETYLGALACTOSAMINE; VACCINE; WATER;

AMEBIASIS; BIOLOGICAL MODEL; CLINICAL FEATURE; COLON MUCOSA; DYSENTERY; ENTAMOEBA HISTOLYTICA; FOOD SAFETY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTESTINE; INTESTINE INFECTION; INTESTINE WALL; LIVER AMEBIASIS; MOLECULE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; WATER QUALITY; XENOGRAFT;

AMEBIASIS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENTAMOEBA HISTOLYTICA; HUMANS; IMMUNITY, NATURAL; ION CHANNELS; LECTINS; MEMBRANE PROTEINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINATION;

EID: 27444435189     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.657     Document Type: Review

References (75)

1. Levine ND, Corliss JO, Cox FE. A newly revised classification of the protozoa. J. Protozool. 27, 37-58 (1980).
2. World Health Organization. Weekly Epidemiologic Record. 72, 97-99 (1997).
3. Blessman J, Ali IK, Nu PA et al. Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J. Clin. Microbiol. 41(10), 4745-4750 (2003).
4. Petri WA Jr, Haque R, Mann BJ. The bittersweet interface of parasite and host: lectin-carbohydrate interactions during human invasion by the parasite Entamoeba histolytica. Ann. Rev. Microbiol. 56, 39-64 (2002). Review of galactose and N-acetyl-D-galactosamine (Gal/GalNAc) lectin and its role in the parasite-host interaction.
5. Gathiram V, Jackson TFHG. A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. S. Afr. Med. J. 72(10), 669-672 (1987).
6. Haque R, Huston C, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N. Engl. J. Med. 348(16), 1565-1573 (2003). Review of the pathogenic mechanisms, immune responses and clinical aspects of amebic colitis and amebic liver abscess.
7. Stanely SL Jr. Amoebiasis. Lancet 361, 1025-1034 (2003). Delineates the steps involved in the innate immune response to amebiasis and reviews pathogenic and clinical aspects of infection.
8. Haque R, Mollah NU, Ali IK et al. Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests. J Clin. Microbiol. 38(9), 3235-3239 (2000).
9. Blessman J, Binh HD, Hung DM, Tannich E, Burchard G. Treatment of amoebic liver abscess with metronidazole alone or in combination with ultrasound-guided needle aspiration: a comparative, prospective and randomized study. Trop. Med. Int. Health 8(11), 1030-1034 (2003).
10. Gatti S, Swierczynski G, Robinson F et al. Amebic infections due to the Entamoeba histolytica-Entamoeba dispar complex: A study of the incidence in a remote rural area of Ecuador. Am. J. Trop. Med. Hyg. 67(1), 123-127 (2002).
11. Stauffer W, Ravdin JI. Entamoeba histolytica: an update. Curr. Opin. Infect. Dis. 16, 479-485 (2003).
12. Abd-Alla M, Wahib A, Ravdin JI. Diagnosis of amebic colitis by antigen capture ELISA in patients presenting with acute diarrhea in Cairo, Egypt. Trop. Med. Int. Health 7, 1-6 (2002).
13. Blessman J, Van Linh P, Nu PA et al. Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in Central Vietnam. Am. J. Trop. Med. Hyg. 66(5), 578-583 (2002).
14. Haque R, Duggal P, Ali IM et al. Innate and acquired resistance to amebiasis in Bangladeshi children. J. Infect. Dis. 186, 547-552 (2002). Describes innate and acquired immunity to amebic infection as well as genetically distinct strains of Entamoeba histolytica in this population.
15. Groseclose SL, Brathwaite WS, Hall PA et al. Summary of notifiable diseases, United States, Morb. Mortal. Wkly Rep. 42, 1-73 (1994).
16. Ravdin JI, Guerrant RL. Role of adherence in cytopathogenic mechanisms of Entamoeba histolytica. Study with mammalian tissue culture cells and human erythrocytes. J. Clin. Invest. 68, 1305-1313 (1981).
17. Ragland BD, Ashley LS, Vaux DL, Petri WA Jr. Entamoeba histolytica: target cells killed by trophozoites undergo apoptosis which is not blocked by bcl-2. Exp. Parasitol. 79(3), 460-467 (1994).
18. Huston CD, Houpt ER, Mann BJ, Hahan CS, Petri WA Jr. Caspase 3-dependent killing of host cells by the parasite Entamoeba histolytica. Cell. Microbiol. 2(6), 617-625 (2000). Demonstrates E. histolytica-induced activation of distal apoptosis components as a mechanism of host cell death.
19. Seydel KB, Li E, Zhang Z, Stanley SL Jr. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology 115(6), 1446-1453 (1998).
20. Eckmann L, Reed SL, Smith JR, Kagnoff MF. Entamoeba histolytica trophozoites induce an inflammatory cytokine response by cultured human cells through the paracrine action of cytolytically released interleukin-1α J. Clin. Invest. 96(3), 1269-1279 (1995).
21. Yu Y, Chadee K. Entamoeba histolytica stimulates interleukin-8 from human colonic epithelial cells without parasite-enterocyte contact. Gastroenterology 112(5), 1536-1547 (1997).
22. Seydel KB, Li E, Swanson PE, Stanley SL Jr. Human intestinal epithelial cells produce pro-inflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect. Immun. 65(5), 1631-1639 (1997).
23. Zhang Z, Mahajan S, Zhang X, Stanley SL Jr. Tumor necrosis factor-α is a key mediator of gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. Infect. Immun. 71(9), 5355-5359 (2003).
24. Stenson WF, Zhang Z, Riehl T, Stanley SL Jr. Amebic infection in the human colon induces Cyclooxygenase-2. Infect. Immun. 69(5), 3382-3388 (2001).
25. Kammanadiminti SJ, Mann BJ, Dutil L, Chadee K. Regulation of Toll-like receptor-2 expression by the Gal-lectin of Entamoeba histolytica. FASEB J. 18(1), 155-157 (2004). Gal/GalNAc lectin upregulates the expression of Toll-like receptor (TLR)-2 through pathways involving a mitogen-activated protein kinase and necrosis fector-κB.
26. Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y. NF-κB and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression. J. Immunol. 166, 4516-4524 (2001).
27. Salata RA, Ravdin JI. The interaction of human neutrophils and Entamoeba histolytica increases cytopathogenicity for liver cell monolayers. J. Infect. Dis. 154(1), 19-26 (1986).
28. Seydel KB, Zhang T, Stanley SL Jr. Neutrophils play a critical role in early resistance to amebic liver abscesses in SCID mice. Infect. Immun. 65(9), 3951-3953 (1997).
29. Seydel KB, Smith SJ, Stanley SL Jr. Innate immunity to amebic liver abscess is dependent on γ-interferon and nitric oxide in a murine model of disease. Infect. Immun. 68(1), 400-402 (2000).
30. Bosco MC, Gusella GL, Espinoza-Delgado I, Longo DL, Varesio L. Interferon-γ upregulates interleukin-8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood 83(2), 537-542 (1994).
31. Seguin R, Mann BJ, Keller K, Chadee K. The tumor necrosis factor- α-stimulating region of galactose-inhibitable lectin of Entamoeba histolytica activates γ-interferon-primed macrophages for amebicidal activity mediated by nitric oxide. Infect. Immun. 65(7), 2522-2527 (1997).
32. Lin JY, Seguin R, Keller K, Chadee K. Tumor necrosis factor-α augments nitric oxide-dependent macrophage cytotoxicity against Entamoeba histolytica by enhanced expression of the nitric oxide synthase gene. Infect. Immun. 62(5), 1534-1541 (1994).
33. Reed SL, Gigli I. Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. J. Clin. Invest. 86, 1815-1822 (1990).
34. Braga LL, Ninomiya H, McCoy JJ et al. Inhibition of complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica. J. Clin. Invest. 90(3), 1131-1137 (1992).
35. Reed SL, Ember JA, Herdman DS, DiScipio RG, Hugli TE, Gigli I. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J. Immunol. 155, 266-274 (1995).
36. + T cells. J. Immunol. 169, 4496-4503 (2002).
37. Haque R, Ali IM, Sack RB, Farr BM, Ramakrishnan G, Petri WA Jr. Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. J. Infect. Dis. 183, 1787-1793 (2001).
38. Ravdin JI, Abd-Alla MD, Welles SL, Reddy S, Jackson TFHG. Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess. Infect. Immun. 71(12), 6899-6905 (2003).
39. Abd-Alla MD, Jackson TFGH, Soong GC, Mazanec M, Ravdin JI. Identification of the Entamoeba hystolytica galacotose-inhibitable lectin epitopes recognized by human immunoglobulin A antibodies following cure of amebic liver abscess. Infect. Immun. 72(7), 3974-3980 (2004).
40. Takahashi T, Gamboa-Dominguez A, Gomez-Mendez TJ et al. Fulminant amebic colitis: analysis of 55 cases. Dis. Colon Rectum 40(11), 1362-1367 (1997).
41. Salata RA, Martinez-Palomo A, Conales L et al. Suppression of T-lymphocyte responses to Entamoeba histolytica antigen by immune sera. Infect. Immun. 58(12), 3941-3946 (1990).
42. Kirch AK, Agossou A, Banla M, Hoffmann WH, Schulz-Key H, Soboslay PT. Parasite-specific antibody and cytokine profiles in newborns from Plasmodium falciparum and Entamoeba histolytica/dispar-infected mothers. Pediatr. Allergy Immunol. 15(2), 133-141 (2004).
43. Pillai DR, Wan PSK, Yau YCW, Ravdin JI, Kain KC. The cysteine-rich region of the Entamoeba histolytica adherence lectin (170-kDa subunit) is sufficient for high affinity Gal/GalNAc-specific binding in vitro. Infect. Immun. 67(8), 3836-3841 (1999).
44. Dodson JM, Lenkowski PW Jr, Eubanks AC et al. Infection and immunity mediated by the carbohydrate recognition domain of the Entamoeba histolytica Gal/GalNAc Lectin. J. Infect. Dis. 179, 460-466 (1999).
45. Chadee K, Petri WA Jr, Innes DJ, Ravdin JI. Rat and human colonic mucins bind to and inhibit the adherence lectin of Entamoeba histolytica. J. Clin. Invest. 80, 1245-1254 (1987).
46. Guerrant RL, Brush J, Ravdin JI, Sullivan JA, Mandell GL. Interaction between Entamoeba histolytica and human polymorphonuclear neutrophils. J. Infect. Dis. 143, 83-93 (1981).
47. Bracha R, Mirelman D. Adherence and ingestion of Escherichia coli serotype 055 by trophozoites of Entamoeba histolytica. Infect. Immun. 40 (3), 882-887 (1983).
48. Mann BJ, Chung CY, Dodson JM, Ashley LS, Braga LL, Snodgrass, TL. Neutralizing monoclonal antibody epitopes of the Entamoeba histolytica galactose adhesin map to the cysteine-rich extracellular domain of the 170-kDa subunit. Infect. Immun. 61, 1772-1778 (1993).
49. Padilla-Vaca F, Ankri S, Bracha R, Koole LA, Mirelman D. Downregulation of Entamoeba histolytica virulence by monoxenic cultivation with Escherichia coli O55 is related to decrease in expression of the light (35-kilodalton) subunit of the Gal/GalNAc lectin. Infect. Immun. 67(5), 2096-2102 (1999).
50. Petri WA Jr, Ravdin JI. Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infect. Immun. 59(1), 97-101 (1991).
51. Gaucher D, Chadee K. Prospect for an Entamoeba histolytica gal-lectin based vaccine. Parasite Immunol. 25, 55-58 (2003). Review of studies using the Gal/GalNAc lectin as a vaccine in animal models.
52. Lotter H, Zhang T, Seydel KB, Stanley SL Jr, Tannich E. Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis. J. Exp. Med. 185(10), 1793-1801 (1997).
53. Soong CJG, Kain KC, Abd-Alla M, Jackson TFHG, Ravdin JI. A recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin is efficacious as a subunit vaccine in the gerbil model of amebic liver abscess. J. Infect. Dis. 171, 645-651 (1995).
54. Lotter H, Khajawa F, Stanley SL Jr, Tannich E. Protection of gerbils from amebic liver abscess by vaccination with a 25-mer peptide derived from the cysteine-rich region of Entamoeba histolytica galactose-specific adherence lectin. Infect. Immun. 68(8), 4416-4421 (2000).
55. Houpt E, Barroso L, Lockhart L et al. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine 22, 611-617 (2004). Demonstrates the effectiveness of a Gal/GalNAc lectin-based vaccine in prevention of amebic colitis in the C3H mouse model.
56. Gaucher D, Chadee K. Construction and immunogenicity of a codon-optimized Entamoeba histolytica Gal-lectin-based DNA Vaccine. Vaccine 20, 3244-3253 (2002).
57. Lotter H, Russmann H, Heesemann J, Tannich E. Oral vaccination with recombinant Yersinia enterocolitica expressing hybrid Type III proteins protects gerbils from amebic liver abscess. Infect. Immun. 72(12), 7318-7321 (2004).
58. Stanley SL Jr. Progress towards development of a vaccine for amebiasis. Clin. Microbiol. Rev. 10(4), 637-649 (1997). Describes different vaccine strategies to prevent amebic infection and a particularly helpful description of serine-rich E. histolytica protein (SREHP)-based vaccines.
59. Wang L, Calderon J, Stanley SL Jr. Short report: identification of B cell epitopes in the serine-rich Entamoeba histolytica protein. Am. J. Trop. Med. Hyg. 57(6), 723-726 (1997).
60. Zhang T, Stanley SL Jr. DNA vaccination with the serine rich Entamoeba histolytica protein (SREHP) prevents amebic liver abscess in rodent models of disease. Vaccine 18, 868-874 (2000).
61. Zhang T, Stanley SL Jr. Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serinerich Entamoeba histolytica protein induces an anti-amebic immune response and protects gerbils from amebic liver abscess. Infect. Immun. 64(5), 1526-1531 (1996).
62. Sultan F, Jin LL, Jobling MG, Holmes RK, Stanley SL Jr. Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect. Immun. 66(2), 462-468 (1998). Oral administration of a holotoxin-like molecule of SREHP and cholera toxin components results in mucosal anti-amebic antibodies in BALB/c mice.
63. Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley SL Jr, Calderwood SB. Oral immunization with attenuated vaccine strains of vibrio cholera expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and antiV cholera antibody responses in mice. Infect. Immun. 65(8), 3118-3125 (1997).
64. Soong CJG, Torian BE, Abd-Alla M, Jackson TFHG, Gatharim V, Ravdin JI. Protection of gerbils from amebic liver abscess by immunization with recombinant Entamoeba histolytica 29-kilodalton antigen. Infect. Immun. 63(2), 472-477 (1995).
65. Zhang Z, Duchene M, Stanley SL Jr. A monoclonal antibody to the amebic lipophosphoglycan-proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with Entamoeba histolytica. Infect. Immun. 70(10), 5873-5876 (2002).
66. Marinets A, Zhang T, Guillen N et al. Protection against invasive amebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica. J. Exp. Med. 186, 1557-1565 (1997).
67. Andra J, Berninghausen O, Leippe M. Membrane lipid composition protects Entamoeba histolytica from self-destruction by its pore-forming toxins. FEBS Lett. 564, 109-115 (2004).
68. Zhang X, Zhang Z, Alexander D, Bracha R, Mirelman D, Stanley SL Jr. Expression of amoebapores is required for full expression of Entamoeba histolytica virulence in the amebic liver abscess but is not necessary for the induction of inflammation or tissue damage in amebic colitis. Infect. Immun. 72(2), 678-683 (2004).
69. Bujanover S, Katz U, Bracha R, Mirelman D. A virulence attenuated amoebapore-less mutant of Entamoeba histolytica and its interaction with host cells. Int. J. Parisitol. 33, 1655-1663 (2003).
70. Bruchhaus I, Loftus BJ, Hall N, Tannich E. The intestinal protozoan parasite Entamoeba histolytica contains 20 cysteine proteinase genes, of which only a small subset is expressed during in vitro cultivaton. Eukaryot. Cell 2, 201-509 (2003).
71. Moncada D, Keller K, Chadee K. Entamoeba histolytica cysteine proteinases disrupt the polymeric structure of colonic mucin and alter its protective function. Infect. Immun. 71(2), 838-844 (2003).
72. Ankri S, Stolarsky T, Mirelman D. Antisense inhibition of expression of cysteine proteinases does not affect Entamoeba histolytica cytopathic or haemolytic activity but inhibits phagocytosis. Mol. Microbiol. 28(4), 777-785 (1998).
73. Zhang Z, Yan L, Seydel KB et al. Entamoeba histolytica cysteine proteinases widi interleukin-1β converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amoebiasis. Mol. Microbiol. 37(3), 542-548 (2000).
74. Martinez-Lopez C, Orozco E, Sanchez T, Garcia-Ferez RM, Hernandez-Hernandez F, Rodriguez MA. The EhADH112 recombinant polypeptide inhibits cell destruction and liver abscess formation by Entamoeba histolytica trophozoites. Cell. Microbiol. 6(4), 367-376 (2004).
75. Simonishvili S, Tsanava S, Sanadze K et al. Entamoeba histolytica: the serine-rich gene polymorphism-based genetic variability of clinical isolates from Georgia. Exp. Parasitol. 110, 313-317 (2005).